doi: 10.1161/hq0102.104125
© 2002 American Heart Association, Inc.
Vascular Biology |
Altered Pattern of Vascular Connexin Expression in Atherosclerotic Plaques
From the Division of Cardiology, Department of Medicine, University Hospital Geneva, Geneva, Switzerland, and LGPD-IBDM (D.B.G.), Campus de Luminy, Marseille France.
Correspondence to François Mach, MD, Cardiology Division, Department of Medicine, University Hospital Geneva, Foundation for Medical Research, 64 Avenue Roseraie, 1211 Geneva 4, Switzerland. E-mail machf{at}cmu.unige.ch
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Paracrine cell-to-cell interactions are crucial events during atherogenesis. However, little is known about the role of direct intercellular communication via gap junctions during this process. We have investigated the expression pattern of 3 vascular gap junction proteins (connexins) in mouse and human atherosclerotic plaques. Low density lipoprotein receptor–deficient mice were fed a high-fat diet for 0, 6, 10, or 14 weeks to induce different stages of atherosclerosis. Connexin37 (Cx37) and Cx40 were detected in the endothelium, and Cx43 was detected in the media of nondiseased aortas. In early atheromas, endothelial and medial connexin expression remained unchanged, and "islets" of Cx43 in smooth muscle cells and Cx37 in macrophages were observed in the neointima. In advanced atheromas, Cx37 was detected in medial smooth muscle cells and in macrophages in the lipid core but not in the endothelium covering the plaques. Cx40 could also no longer be detected in the endothelium covering the plaques. Cx43, on the other hand, was detected in the endothelium covering the shoulder of the plaques and also sparsely in neointimal smooth muscle cells. Similar results were obtained for human carotid arteries. In conclusion, vascular connexins are differentially expressed by atheroma-associated cells within lesions. These observations suggest a role for gap junctional intercellular communication during atherogenesis.
Key Words: atherosclerosis • gap junctions • connexins • endothelium • macrophages • smooth muscle
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Atherosclerosis, the principle cause of death in Western societies, is a progressive disease that generally begins in childhood and has clinical manifestations in middle age or later.1 Atherosclerotic plaques have 3 principal components: (1) cells, including endothelial cells, smooth muscle cells, macrophages, and T lymphocytes; (2) connective tissue extracellular matrix; and (3) intracellular and extracellular lipid deposits. These 3 components occur in varying proportions in different plaques, giving rise to a spectrum of lesions. Typically, the superficial fibrous cap is composed of smooth muscle cells with dense connective tissue and a few inflammatory cells. The cellular area beneath and to the side of the cap, the shoulder, consists of a mixture of macrophages, smooth muscle cells, and T lymphocytes, whereas the deeper necrotic core is a disorganized mass of lipids, cellular debris, and lipid-laden foam cells.2,3
Initiation and progression of the atherosclerotic plaque involve complex patterns of interaction between the cells of the arterial wall, in which cytokines, chemokines, and growth factors are known to play a critical role.4,5 Apart from these paracrine signaling mechanisms, another form of cell-to-cell interaction involves direct intercellular communication via gap junctions. Gap junctions are clusters of transmembrane channels that link the cytoplasmic compartments of neighboring cells, allowing a direct exchange of ions and second messengers.6 A gap junction channel is constructed from a pair of hemichannels named connexons; each connexon is assembled from 6 connexin molecules. The connexins form a multigene family consisting of at least 15 members in mammals.7 Each connexin forms channels with different properties of gating, permeability, and selective interaction with other connexins.8 Within 1 organ or cell type, various connexins can be expressed. Three connexins, connexin37 (Cx37), Cx40, and Cx43, are reported to be expressed in the vascular wall.9–17 Endothelial cells and smooth muscle cells have distinctive but overlapping connexin expression patterns. Whereas Cx37 and Cx40 (and also, depending on the type of vessel and its position in the vascular tree, Cx43) are coexpressed in the endothelium,18,19 smooth muscle cells in the media predominantly express Cx43.20 Some reports suggest that Cx40 may also be expressed in vascular smooth muscle cell types.14,21,22
Current knowledge about vascular gap junctions is growing rapidly. These communication pathways have been implicated in a variety of vascular functions, such as coordination of vasomotor responses, regulation of angiogenesis, repair of the endothelial lining, and senescence.23–27 In addition, connexin expression is altered in vascular disease states such as hypertension and after balloon catheter injury.28–30 However, information regarding the involvement of vascular connexins in atherogenesis is fragmentary. In the early stages of human coronary atherosclerosis, an upregulation of Cx43 in the intimal smooth muscle layer, which was reduced in advanced atheromatous lesions, has been described.31 Hypercholesteremia-induced atherosclerosis in rabbits resulted in Cx43 expression associated with macrophage foam cells, but there were reduced levels of this connexin between smooth muscle cells.29 At last, a genetic polymorphism has been recently discovered in the human Cx37 protein that appears to be a prognostic marker for atherosclerotic plaque development.32 Considering the crucial role of paracrine cell-to-cell interactions in the pathogenesis of atherosclerosis as well as the important roles of gap junction-mediated cell-to-cell communication in vascular physiology, we sought to investigate the expression patterns of the 3 vascular connexins in normal vessels and in advanced atherosclerotic lesions.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
LDL receptor (LDLR)-deficient (LDLR-/-) mice,33 aged 10 weeks, with a C57BL/6J background (Jackson Laboratory, Bar Harbor, Me) consumed a high-cholesterol diet (product No. D12108 [1.25% cholesterol and 0% cholate], Research Diets, Inc) for 6, 10, or 14 weeks. Then the mice were euthanized, and their aortas were taken. Age-matched LDLR-/- mice that were not placed on the diet were used as controls. The aortic arches were perfused with 0.9% NaCl and snap-frozen in OCT compound (Tissue-Tek). Surgical specimens of human carotid atheroma were obtained by protocols approved by the Human Investigation Review Committee at the Geneva Hospital. Samples were rinsed with 0.9% NaCl and snap-frozen in OCT compound.
Antibodies
Polyclonal antibodies raised in rabbits against oligopeptides of the carboxy terminus of the gap junction proteins Cx37 (amino acids 315 to 331)15,34 or Cx40 (amino acids 335 to 356)35 were used. Rabbit polyclonal antibodies against Cx43, smooth muscle (SM) myosin heavy chain (MHC), or von Willebrand factor were purchased from Zymed Laboratories, Biomedical Technologies Inc, and Dako, respectively. Mouse monoclonal antibodies against human 
-SM actin (SMA), human CD31 (anti–endothelial cell), or HAM-56 (anti-macrophage) and a rat monoclonal antibody against mouse macrophages (MOMA-2) were purchased from Dako, Sigma Immunochemical, Dako, and Biosource International, respectively.
Immunohistochemistry
For cell identification, serial sections of 5 µm were cut, air-dried, and fixed in acetone for 5 minutes at -20°C. Sections were preincubated with 8% normal horse or goat serum (Sigma) for 15 minutes, then incubated with cell-selective primary antibody (anti-SMA 1:100, anti–von Willebrand factor 1:1000, anti-CD31 1:50, anti–HAM-56 1:100, anti–SM-MHC 1:10, or anti–MOMA-2 1:10) for 90 minutes, followed by biotinylated secondary antibody (anti-rabbit or anti-mouse IgG 1:100, anti-rat IgG 1:8000, Vector Laboratories) for 45 minutes and avidin–biotin–alkaline phosphatase complex (Vectastain ABC-AP kit), and visualized with Vector red (Vector Laboratories). Sections were counterstained with Harris hematoxylin solution (Sigma) for 8 seconds or with Mayer’s hemzlin solution (Merck) for 1 minute. All steps were performed at room temperature, and between steps, the cells were rinsed with PBS. Specificity was confirmed by omitting the primary antibody.
For connexin staining, serial sections of 5 µm were cut, air-dried, and fixed in methanol for 5 minutes at -20°C. Sections were incubated successively with 0.2% Triton X-100 in PBS for 1 hour, 0.5 mol/L NH4Cl in PBS for 15 minutes, and PBS supplemented with 2% BSA for another 30 minutes. Sections were then incubated overnight with primary antibody at appropriate dilutions (for anti-Cx37, 3 µg/mL; for anti-Cx40, 3 µg/mL; and for anti-Cx43, 1 µg/mL) and 10% normal goat serum in PBS. After they were rinsed, the sections were incubated with secondary antibodies conjugated to FITC (1:1000, Jackson Laboratories) for 4 hours or with biotinylated secondary antibodies (1:100, Vector Laboratories) followed by the detection described above. All steps were performed at room temperature, and between the incubation steps, the cells were rinsed with PBS. Some sections were counterstained with Evans blue solution (0.03% in PBS) for 1 minute. Specificity of the Cx43 labeling was confirmed by preabsorption for 15 minutes at room temperature with its immunogenic peptide (20 µg/mL, Zymed Laboratories). Specificity of the Cx37 or Cx40 labeling was checked by replacing the primary antibody with preimmune serum.
For double fluorescence staining, the protocol described for connexin staining was followed. CD31, SMA, or HAM-56 was detected with an anti-mouse secondary antibody conjugated to FITC (1:1500, Jackson Laboratories), and the connexins were detected with an anti-rabbit secondary antibody conjugated to Texas red (1:2000, Jackson Laboratories).
Sections were examined on a Zeiss Axiophot microscope equipped with fluorescence and appropriate filters. Photographs were taken on a computer with use of a CCD camera (Photonic Science) and Image Access software (version 2.04). To confirm the coexpression of connexins with cell markers, slides were further examined with a confocal laser scan fluorescence inverted microscope (CLSM 410, Zeiss). Images were processed with Adobe Photoshop 5.0 (Adobe System).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
To study the expression pattern of vascular connexins during atherogenesis, we used LDLR-/- mice and exposed them to a high-cholesterol diet for 6, 10, or 14 weeks to induce, in a reproducible manner, atherosclerotic plaques at different stages of development. These atherosclerotic lesions typically developed at lesion-prone sites, such as the lesser curvature of the aortic arch and the outflow tracts of the innominate, left common carotid, and left subclavian arteries. Age-matched LDLR-/- mice without dietary intervention were used as controls and did indeed show no signs of plaque formation at those localizations (Figure 1). Despite some small variations in the histological morphology, lesions after 6, 10, and 14 weeks of dietary intervention could be divided in 3 categories, ie, intimal thickening, early atheroma, and advanced atheroma, respectively. Whereas we observed lipid deposition in the vascular wall of all mice after 6 weeks of diet (data not shown), increased intimal thickness was present in only a small fraction of them. Lesions after 10 weeks of diet, defined as early atheroma, include initial fatty streaks as well as intermediate lesions of atherosclerosis. The complex advanced lesions after 14 weeks of dietary intervention shared a number of common features: a superficial fibrous cap of mainly smooth muscle cells, an area containing mainly inflammatory cells in the shoulder of the plaque beneath the cap, and a lipid-rich core.
|
The expression patterns of Cx37, Cx40, and Cx43 in the different stages of atherosclerosis were investigated in serial sections by immunolabeling with fluorescence detection (FITC, green signal; Figure 2) as well as enzymatic detection (alkaline phosphatase, red signal; Figure 3). In control aortas, a clear Cx37 and Cx40 immunolabeling was observed in the endothelium. No signal for either connexin could be detected in the media at this time point (Figure 2A and 2B). However, Cx43 was abundantly expressed in the medial smooth muscle layer but could not be detected in the endothelium of control aortas (Figure 2C). After 6 weeks of diet, a similar expression pattern was observed for all 3 connexins (Figure 2D-F). After 10 weeks of diet, Cx37 and Cx40 were still present in the endothelial layer (Figure 2G and 2H). In addition, a Cx37 signal was observed in small "islets" in the neointima of these early atheromas (arrowhead in Figure 2G). At this time point, Cx43 expression was observed in the medial smooth muscle layer (Figure 2I) and also appeared in the neointima as small islets at sites different from the Cx37 islets previously mentioned (arrowheads in Figure 2I). In the shoulder area of advanced lesions, endothelial expression of Cx37 and Cx40 was no longer detected (Figure 2J and 2K). In contrast, a punctate labeling of Cx43 was observed in the endothelium in this shoulder region of advanced plaques (arrow in Figure 2L). None of the 3 vascular connexins was detected in the endothelium covering the center of advanced lesions (Table).
|
|
|
To define the cell types expressing the different connexins within atherosclerotic plaques, we performed immunostaining with enzymatic detection on consecutive cryosections. The advantage of enzymatic detection is that histological details of the plaque are preserved. However, this method is less sensitive than fluorescence, leading to an apparent loss of connexin staining in the endothelium. Cx43 immunostaining was colocalized with smooth muscle cells in the media of mouse control aortas (Figure 3A and 3B). As expected, no signal was obtained with the macrophage marker MOMA-2 or with Cx37 antibodies in these nondiseased aortas (Figure 3C and 3D). In early atheromas induced by 10 weeks of a cholesterol-rich diet, Cx43 was observed in smooth muscle cells of the media beneath the plaque (Figure 3E and 3F). In the neointima of early atheromas, Cx43 was colocalized with the smooth muscle cell marker (eg, see arrows in Figure 3E and 3F), whereas Cx37 was colocalized with the macrophage marker (arrows in Figure 3G and 3H). Note that the latter colocalization does not imply that all macrophages express Cx37; in fact, most are devoid of the 3 vascular connexins. In all 5 mice tested, a strong Cx37 immunostaining was associated with macrophages in the core of advanced atherosclerotic plaques (asterisks in Figure 3K and 3L). In addition, Cx43 immunoreactivity was observed in or close to the core in 2 of 5 advanced lesions. We did not observe immunostaining for Cx37, Cx40 (not shown), and Cx43 in superficial macrophages in advanced atherosclerotic plaques (Figure 3J through 3L). At this time point, only a faint Cx43 immunoreactivity associated with neointimal smooth muscle cells was detected (Figure 3I and 3J). Interestingly, we observed a strong Cx37 immunostaining in the media beneath the plaques in all 5 mice tested (arrow in Figure 3K). Cx43 immunoreactivity was observed in only 2 of 5 advanced lesions at this localization (Figure 3J).
The pattern of connexin expression in human atherosclerotic plaques was similar to murine expression patterns (online Figures I and II, which can be accessed at http://atvb.ahajournals.org). The results describing connexin expression at different stages of atherosclerotic plaque development are summarized in the Table.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We examined the expression of Cx43, Cx40, and Cx37, the 3 major native connexins of the vascular system, during the experimental induction of atherosclerosis. To this end, we studied mice deficient for the LDLR that feature reproducible atherosclerotic plaques after being fed a high-cholesterol diet for 6, 10, or 14 weeks. In the present study, we report a dynamic pattern of vascular connexin expression in atherosclerotic lesions. At last, we compared connexin expression of advanced mouse and human atherosclerotic plaques (see Figure 4 for a schematic summary).
|
The LDLR removes cholesterol-rich IDL and LDL from plasma, thereby regulating the plasma cholesterol level. Mice lacking the LDLR have plasma cholesterol levels that are 2 times normal33 but respond to moderate amounts of dietary cholesterol with a major increase in cholesterol content of IDL and LDL particles and development of atherosclerotic plaques throughout the aorta. The lesions resemble human lesions and progress over time from an intimal thickening to a complex lesion with a fibrous cap.36 Lesion development can be accelerated by a high-fat high-cholesterol diet,37 as used in the present study.
The endothelium covering the advanced atherosclerotic plaque did not express detectable levels of Cx40 and Cx37. However, these connexins were abundantly expressed in the endothelium next to the plaques and earlier during atherogenesis as well as in the aortic endothelium of control mice, an expression pattern consistent with previous studies involving cows, micropigs, and rats.17,18 Furthermore, we observed that Cx43, although absent in control aortic endothelium, appeared in the endothelium at the shoulder region of advanced atherosclerotic plaques, a localization known to experience disturbed hemodynamic forces. In a recent study examining rat aorta and its bifurcation, high levels of Cx43 in the endothelium were associated with areas facing turbulent blood flow.18 In addition, several in vitro studies show a positive correlation between Cx43 expression and mechanical load or disturbed flow patterns.38,39 Taken together, the above-mentioned studies suggest a causal link between endothelial Cx43 expression and hemodynamic conditions that may be relevant to focal vulnerability to atherosclerosis. However, the late stage in mouse atherogenesis, at which we observed the induction of endothelial Cx43 expression, suggests that Cx43 induction may participate in endothelium dysfunction in the late end stage of the disease. Apart from hemodynamic forces, other factors are reported to affect endothelial connexins. For example, age-related downregulation of all 3 endothelial connexins have been described in rat aortas.27 Treatment with tumor necrosis factor-, a cytokine that promotes endothelial cell migration, leads to upregulation of Cx43 and downregulation of Cx37 and Cx40 in human umbilical vein endothelial cells,40 whereas migration of mouse endothelial cells induced by mechanical wounding leads to the upregulation of Cx43 and downregulation of Cx37 but leaves the expression of Cx40 unaffected.26 In addition, Cx43 and Cx37 in bovine aortic endothelial cells are reported to be differentially regulated by cell density and growth.41 At last, in regenerating endothelium after denudation injury, the expression of all 3 endothelial connexins initially declines but progressively increases during regeneration although at a different rate for all 3 connexins.42 Whether the disappearance of all 3 vascular connexins that we observed in the endothelium covering advanced atherosclerotic plaques participates in endothelial regeneration or migration processes remains to be established.
Adherence of blood monocytes to the dysfunctional endothelium at lesion-prone sites is the earliest observable cellular event in the development of atherosclerosis.2 Thereafter, monocytes migrate in response to chemotactic stimuli into the subendothelial space, where they undergo proliferation and lipid accumulation, ultimately resulting in the foam cells typical for atherosclerotic lesions. We observed a strong immunolabeling for Cx37 in the core of mouse and human atherosclerotic lesions. This Cx37 immunostaining was colocalized with a marker for macrophages. In addition, we detected a diffuse Cx43 signal throughout the neointima of mouse and human atherosclerotic plaques that may be confined to smooth muscle and inflammatory cells. Indeed, Cx43 mRNA expression has been reported in macrophage foam cells in human and rabbit atherosclerotic plaques.29,43 Interestingly, freshly isolated blood monocytes do not express connexin mRNA or protein.43,44 Thus, the expression of Cx37 and Cx43 in macrophages in atherosclerotic lesions clearly indicates that gene expression of these gap junction proteins is stimulated on the migration and subsequent differentiation of monocytes/macrophages, suggesting a role for direct cell-to-cell communication in this process.
Cx43 was expressed in different vascular smooth muscular compartments in nondiseased aortas and in atherosclerotic plaques. Whereas Cx43 was the principal gap junction protein present in the media of mouse aortas, an observation consistent with previous studies involving humans, cows, micropigs, and rats,17,20 we also observed Cx43 in the neointima of mouse and human atherosclerotic plaques. These observations are in agreement with the hypothesis recently proposed by Ko et al45 that Cx43 gap junctional intercellular communication in different smooth muscle cell phenotypes may be linked to different functions of smooth muscle cells, such as the ability of smooth muscle cells to coordinate the synthesis of extracellular matrix components, to maintain the functional integrity of elastic media, and/or to regulate the repair and formation of the intima in vascular injury and disease. We observed a trend toward reduced levels of neointimal Cx43 expression with continuing lesion progression in mouse atherosclerotic plaques, an effect that has also been reported during human atherogenesis.31 Interestingly, we have found that Cx37 was expressed in the media beneath the atherosclerotic plaque, a region in which Cx43 was decreased or often even no longer detected. Considering the differential permeabilities of Cx43 and Cx37 gap junction channels,26,46 the change in connexin expression in this particular group of smooth muscle cells will certainly lead to a marked change in the pattern of intercellular communication that may affect the function of the smooth muscle cells. An additional connexin isoform, Cx40, has been reported in cultured rat aortic smooth muscle cells,21,22 and although this connexin has also been reported in the smooth muscle cells of intact small resistance vessels,14 it does not appear to be present in the intact mouse aorta.
In summary, we have found that the expression of vascular connexins is differentially regulated during the process of atherosclerosis and that this differential regulation in human plaques largely resembles the one of mice. The change in distribution of individual connexins over the different compartments of the atherosclerotic plaque suggests that these connexins may differentially regulate the cell-to-cell transfer of factors important for the development of the lesion. Elucidation of how the changes in connexin expression participate in the development of atherosclerotic plaques awaits the availability of novel mouse models in which the expression level of vascular connexins is altered in LDLR-/- mice. At this point, our data indicating that vascular connexins are differentially expressed by atheroma-associated cells within lesions raise the intriguing possibility that apart from paracrine cell-cell communication, direct cell-cell communication via gap junctions may contribute to the still-obscure pathogenesis of atherosclerosis in humans.
|
Acknowledgments |
|---|
This work was supported by grants from the Swiss National Science Foundation (grant 3800-054965.98/1 to Dr Mach), the Fondation Leenaards (to Drs Kwak and Mach), and the E.E.C. (No. QLG1-CT-1999-00516 to Dr Gros). We thank G. Pelli for excellent technical assistance, I. Scerri and Dr M.L. Bochaton-Piallat for help with confocal imaging, and Dr M. Chanson for critical reading of the manuscript.
Received September 13, 2001; accepted October 2, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000; 247: 349–358.[CrossRef][Medline] [Order article via Infotrieve]
2. Schoen FJ, Cotran RS. Blood vessels.In: Cotran RS, Kumar V, Collins T, eds. Robbins Pathologic Basis of Disease. Philadelphia, PA: WB Saunders Co;. 1999: 493–541.
3. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995; 57: 791–804.[CrossRef][Medline] [Order article via Infotrieve]
4.
Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
5. Gerszten RE, Mach F, Sauty A, Rosenzweig A, Luster AD. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med. 2000; 136: 87–92.[CrossRef][Medline] [Order article via Infotrieve]
6. Kumar N, Gilula NB. The gap junction communication channel. Cell. 1996; 84: 381–388.[CrossRef][Medline] [Order article via Infotrieve]
7. White TW, Paul DL. Genetic diseases and gene knockouts reveal diverse connexin functions. Annu Rev Physiol. 1999; 61: 283–310.[CrossRef][Medline] [Order article via Infotrieve]
8. Bruzzone R, White TW, Paul DL. Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem. 1996; 238: 1–27.[Medline] [Order article via Infotrieve]
9.
Larson DM, Haudenschild CC, Beyer EC. Gap junction messenger RNA expression by the vascular wall cells. Circ Res. 1990; 66: 1074–1080.
10.
Bastide B, Neyses L, Ganten D, Paul M, Willecke K, Traub O. Gap junction protein connexin40 is preferentially expressed in vascular endothelium and conductive bundles of rat myocardium and is increased under hypertensive conditions. Circ Res. 1993; 73: 1138–1149.
11. Bruzzone R, Haefliger JA, Gimlich RL, Paul DL. Connexin40, a component of gap junctions in vascular endothelium, is restricted in its ability to interact with other connexins. Mol Biol Cell. 1993; 4: 7–20.[Abstract]
12. Reed KE, Westphale EM, Larson DM, Wang HZ, Veenstra RD, Beyer EC. Molecular cloning and functional expression of human connexin37, an endothelial cell gap junction protein. J Clin Invest. 1993; 91: 997–1004.[Medline] [Order article via Infotrieve]
13. Rennick RE, Connat JL, Burnstock G, Rothery S, Severs NJ, Green CR. Expression of connexin43 gap junctions between cultured vascular smooth muscle cells is dependent upon phenotype. Cell Tissue Res. 1993; 271: 323–332.[CrossRef][Medline] [Order article via Infotrieve]
14. Little TL, Beyer EC, Duling BR. Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth muscle and endothelium in vivo. Am J Physiol. 1995; 268: H729–H739.[Medline] [Order article via Infotrieve]
15. VanRijen HVM, VanKempen MJA, Analbers LJS, Rook MB, VanGinneken ACG, Gros D, Jongsma HJ. Gap junctions in human umbilical cord endothelial cells contains multiple connexins. Am J Physiol. 1997; 272: C117–C130.[Medline] [Order article via Infotrieve]
16.
Yeh HI, Dupont E, Coppen S, Rothery S, Severs NJ. Gap junction localization and connexin expression in cytochemically identified endothelial cells of arterial tissue. J Histochem Cytochem. 1997; 45: 539–550.
17. VanKempen MJA, Jongsma HJ. Distribution of connexin37, connexin40 and connexin43 in the aorta and coronary artery of several mammals. Histochem Cell Biol. 1999; 112: 479–486.[CrossRef][Medline] [Order article via Infotrieve]
18.
Gabriels JE, Paul DL. Connexin43 is highly localized to sites of disturbed flow in rat aortic endothelium but connexin37 and connexin40 are more uniformly distributed. Circ Res. 1998; 83: 636–643.
19. Hong T, Hill CE. Restricted expression of the gap junctional protein connexin43 in the arterial system of the rat. J Anat. 1998; 193: 583–593.[CrossRef]
20. Blackburn JP, Connat JL, Severs NJ, Green CR. Connexin43 gap junction levels during development of the thoracic aorta are temporally correlated with elastic laminae deposition and increased blood pressure. Cell Biol Int. 1997; 21: 87–97.[CrossRef][Medline] [Order article via Infotrieve]
21. Moore LK, Beyer EC, Burt JM. Characterization of gap junction channels in A7r5 vascular smooth muscle cells. Am J Physiol. 1991; 260: C975–C981.[Medline] [Order article via Infotrieve]
22.
Kwak BR, Jongsma HJ. Selective inhibition of gap junction channel activity by synthetic peptides. J Physiol (Lond). 1999; 516: 679–685.
23.
Christ GJ, Spray DC, El-Sabban M, Moore LK, Brink PR. Gap junctions in vascular tissues: evaluating the role of intercellular communication in the modulation of vasomotor tone. Circ Res. 1996; 79: 631–646.
24.
DeWit C, Roos F, Bolz SS, Kirchhoff S, Kruger O, Willecke K, Pohl U. Impaired conduction of vasodilatation along arterioles in connexin40-deficient mice. Circ Res. 2000; 86: 649–655.
25.
Pepper MS, Spray DC, Chanson M, Montesano R, Orci L, Meda P. Junctional communication is induced in migrating capillary endothelial cells. J Cell Biol. 1989; 109: 3027–3038.
26.
Kwak BR, Pepper MS, Gros DB, Meda P. Inhibition of endothelial wound repair by dominant negative connexin inhibitors. Mol Biol Cell. 2001; 12: 831–845.
27.
Yeh HI, Chang HM, Lu WW, Lee YN, Ko YS, Severs NJ, Tsai CH. Age-related alteration of gap junction distribution and connexin expression in rat aortic endothelium. J Histochem Cytochem. 2000; 48: 1377–1389.
28.
Haefliger JA, Castillo E, Waeber G, Bergonzelli G, Aubert JF Sutter E, Nicod P, Waeber B, Meda P. Hypertension increases connexin43 in a tissue specific manner. Circulation. 1997; 95: 1007–1014.
29. Polacek D, Bech F, McKinsey JF, Davies PF. Connexin43 gene expression in the rabbit arterial wall: effects of hypercholesterolemia, balloon injury and their combination. J Vasc Res. 1996; 34: 19–30.
30.
Yeh HI, Lupu F, Dupont E, Severs NJ. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Arterioscler Thromb Vasc Biol. 1997; 17: 3174–3184.
31.
Blackburn JP, Peters NS, Yeh HI, Rothery S, Green CR, Severs NJ. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995; 15: 1219–1228.
32. Boerma M, Forsberg L, VanZeijl L, Morgenstern R, DeFaire U, Lemne C, Erlinge D, Thulin T, Hong Y, Cotgreave IA. A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development. J Intern Med. 1999; 246: 211–218.[CrossRef][Medline] [Order article via Infotrieve]
33. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesteremia in LDL receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993; 92: 883–893.[Medline] [Order article via Infotrieve]
34.
Delorme B, Dahl E, Jarry-Guichard T, Marics I, Briand JP, Willecke K, Gros D, Théveniau-Ruissy M. Expression pattern of connexin gene products at early developmental stages of the mouse cardiovascular system. Circ Res. 1997; 81: 423–437.
35.
Gros D, Jarry-Guichard T, TenVelde I, DeMazière A, VanKempen MJA, Davoust J, Briand JP, Moorman AFM, Jongsma HJ. Restricted distribution of connexin40, a gap junction protein, in mammalian heart. Circ Res. 1994; 74: 839–851.
36.
Knowles JW, Maeda N. Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000; 20: 2336–2345.
37. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994; 93: 1885–1893.[Medline] [Order article via Infotrieve]
38.
Cowan DB, Lye SJ, Langille BL. Regulation of vascular connexin43 gene expression by mechanical loads. Circ Res. 1998; 82: 786–793.
39.
De Paola N, Davies PF, Pritchard WF Jr, Florez L, Harbeck N, Polacek DC. Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro. Proc Natl Acad Sci U S A. 1999; 96: 3154–3159.
40. VanRijen HVM, VanKempen MJA, Postma S, Jongsma HJ. Tumour necrosis factor alpha alters the expression of connexin43, connexin40, and connexin37 in human umbilical vein endothelial cells. Cytokine. 1998; 10: 258–264.[CrossRef][Medline] [Order article via Infotrieve]
41. Larson DM, Wrobleski MJ, Sagar GDV, Westphale EM, Beyer EC. Differential regulation of connexin43 and connexin37 in endothelial cells by density, growth and TGF-ß1. Am J Physiol. 1997; 272: C405–C415.[Medline] [Order article via Infotrieve]
42.
Yeh HI, Lai YJ, Chang HM, Ko YS, Severs NJ, Tsai CH. Multiple connexin expression in regenerating arterial endothelial gap junctions. Arterioscler Thromb Vasc Biol. 2000; 20: 1753–1762.
43. Polacek D, Lal R, Volin MV, Davies PF. Gap junctional communication between vascular cells: induction of connexin43 messenger RNA in macrophage foam cells of atherosclerotic lesions. Am J Pathol. 1993; 142: 593–606.[Abstract]
44.
Jara PI, Boric MP, Saez JC. Leukocytes express connexin 43 after activation with lipopolysaccharide and appear to form gap junctions with endothelial cells after ischemia reperfusion. Proc Natl Acad Sci U S A. 1995; 92: 7011–7015.
45.
Ko YS, Yeh HI, Haw M, Dupont E, Kaba R, Plenz G, Robenek H, Severs NJ. Differential expression of connexin43 and desmin defines two subpopulations of medial smooth muscle cells in the human internal mammary artery. Arterioscler Thromb Vasc Biol. 1999; 19: 1669–1680.
46.
Elfgang C, Eckert R, Lichtenberg-Fraté H, Butterweck A, Traub O, Klein R, Hulser D, Willecke K. Specific permeability and selective formation of gap junction channels in connexin-transfected HeLa cells. J Cell Biol. 1995; 129: 805–817.
This article has been cited by other articles:
 |
|
 |
|
  M. Song, X. Yu, X. Cui, G. Zhu, G. Zhao, J. Chen, and L. Huang Blockade of Connexin 43 Hemichannels Reduces Neointima Formation After Vascular Injury by Inhibiting Proliferation and Phenotypic Modulation of Smooth Muscle Cells Experimental Biology and Medicine, October 1, 2009; 234(10): 1192 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Johnstone, J. Ross, M. J. Rizzo, A. C. Straub, P. D. Lampe, N. Leitinger, and B. E. Isakson Oxidized Phospholipid Species Promote in Vivo Differential Cx43 Phosphorylation and Vascular Smooth Muscle Cell Proliferation Am. J. Pathol., August 1, 2009; 175(2): 916 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Burnier, P. Fontana, A. Angelillo-Scherrer, and B. R. Kwak Intercellular Communication in Atherosclerosis Physiology, February 1, 2009; 24(1): 36 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Veliz, F. G. Gonzalez, B. R. Duling, J. C. Saez, and M. P. Boric Functional role of gap junctions in cytokine-induced leukocyte adhesion to endothelium in vivo Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1056 - H1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C Villar, A. J Hobbs, and A. Ahluwalia Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor J. Endocrinol., June 1, 2008; 197(3): 447 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Chadjichristos, S. Morel, J.-P. Derouette, E. Sutter, I. Roth, A. C. Brisset, M.-L. Bochaton-Piallat, and B. R. Kwak Targeting Connexin 43 Prevents Platelet-Derived Growth Factor-BB-Induced Phenotypic Change in Porcine Coronary Artery Smooth Muscle Cells Circ. Res., March 28, 2008; 102(6): 653 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao, C. P. Regan, I. Manabe, G. K. Owens, K. H. Day, D. N. Damon, and B. R. Duling Smooth Muscle-Targeted Knockout of Connexin43 Enhances Neointimal Formation in Response to Vascular Injury Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1037 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Isakson, G. Kronke, A. Kadl, N. Leitinger, and B. R. Duling Oxidized Phospholipids Alter Vascular Connexin Expression, Phosphorylation, and Heterocellular Communication Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2216 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Chadjichristos, C. M. Matter, I. Roth, E. Sutter, G. Pelli, T. F. Luscher, M. Chanson, and B. R. Kwak Reduced Connexin43 Expression Limits Neointima Formation After Balloon Distension Injury in Hypercholesterolemic Mice Circulation, June 20, 2006; 113(24): 2835 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Ebong, S. Kim, and N. DePaola Flow regulates intercellular communication in HAEC by assembling functional Cx40 and Cx37 gap junctional channels Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2015 - H2023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Isakson, D. N. Damon, K. H. Day, Y. Liao, and B. R. Duling Connexin40 and connexin43 in mouse aortic endothelium: evidence for coordinated regulation Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1199 - H1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Ginsburg, M. P. Donahue, and L. K. Newby Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dai, M. R. Kaazempur-Mofrad, S. Natarajan, Y. Zhang, S. Vaughn, B. R. Blackman, R. D. Kamm, G. Garcia-Cardena, and M. A. Gimbrone Jr. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature PNAS, October 12, 2004; 101(41): 14871 - 14876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W Wong, T. Christen, and B. R Kwak Connexins in leukocytes: shuttling messages? Cardiovasc Res, May 1, 2004; 62(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. SAEZ, V. M. BERTHOUD, M. C. BRANES, A. D. MARTINEZ, and E. C. BEYER Plasma Membrane Channels Formed by Connexins: Their Regulation and Functions Physiol Rev, October 1, 2003; 83(4): 1359 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. Tulenko Regulating Cross-Talk Between Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1707 - 1709. [Full Text] [PDF]
|
|
|
|
|
|
H.-I Yeh, C.-S. Lu, Y.-J. Wu, C.-C. Chen, R.-C. Hong, Y.-S. Ko, M.-S. Shiao, N. J. Severs, and C.-H. Tsai Reduced Expression of Endothelial Connexin37 and Connexin40 in Hyperlipidemic Mice: Recovery of Connexin37 After 7-Day Simvastatin Treatment Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1391 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Kwak, N. Veillard, G. Pelli, F. Mulhaupt, R. W. James, M. Chanson, and F. Mach Reduced Connexin43 Expression Inhibits Atherosclerotic Lesion Formation in Low-Density Lipoprotein Receptor-Deficient Mice Circulation, February 25, 2003; 107(7): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Eugenin, M. C. Branes, J. W. Berman, and J. C. Saez TNF-{alpha} Plus IFN-{gamma} Induce Connexin43 Expression and Formation of Gap Junctions Between Human Monocytes/Macrophages That Enhance Physiological Responses J. Immunol., February 1, 2003; 170(3): 1320 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Oviedo-Orta and W. H. Evans Gap junctions and connexins: potential contributors to the immunological synapse J. Leukoc. Biol., October 1, 2002; 72(4): 636 - 642. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||